Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Small Pharma Inc V.DMT

Healthcare
Small Pharma Inc. is a biotechnology company focused on short-duration psychedelic therapies for mental health conditions. The Company is focused on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions that are scalable, commercially differentiated, and conveniently dosed, with the goal of addressing key unmet needs in the treatment of... see more

Recent & Breaking News (TSXV:DMT)

Small Pharma Reports Fiscal Third Quarter 2021 Highlights

GlobeNewswire January 31, 2022

Small Pharma to Attend Upcoming Healthcare Conferences in January 2022

GlobeNewswire January 4, 2022

Small Pharma to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6, 2021

GlobeNewswire December 1, 2021

Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

GlobeNewswire November 18, 2021

Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder

GlobeNewswire November 15, 2021

Small Pharma to Attend Upcoming Healthcare Conferences in November 2021

GlobeNewswire November 12, 2021

Small Pharma Reports Second Quarter Highlights

GlobeNewswire November 1, 2021

Small Pharma (TSXV:DMT) granted European patent

Trevor Abes  October 25, 2021

European Patent Grant Strengthens Small Pharma's Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders

GlobeNewswire October 25, 2021

Small Pharma (TSXV:DMT) granted fast-track designation for DMT-assisted therapy

Trevor Abes  October 21, 2021

Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder

GlobeNewswire October 21, 2021

Small Pharma Announces Upgrade to the OTCQB® and DTC Eligibility

GlobeNewswire October 20, 2021

Small Pharma (TSXV:DMT) doses first patient in trial

Brieanna McCutcheon  October 19, 2021

First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

GlobeNewswire October 19, 2021

Small Pharma to Restate Financial Statements to Reflect IFRS Fair Value of Convertible Notes and Share Options

GlobeNewswire October 18, 2021

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

PR Newswire October 11, 2021

Small Pharma to Present at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021

GlobeNewswire October 7, 2021

Negev Capital doubles down on Small Pharma (TSXV:DMT)

Trevor Abes  September 21, 2021

Small Pharma Successfully Completes Phase I Clinical Trial of DMT in Combination with Supportive Psychotherapy

GlobeNewswire September 21, 2021

Small Pharma Included in AdvisorShares® Newly Launched Psychedelics ETF

GlobeNewswire September 20, 2021